Interview with Wu Xiaobing, General Manager, Pfizer China
It seems like there’s a lot to be happy about here: Pfizer is ranked number 1 multinational R&D-based biopharmaceutical company in China, where you also have two world-class R&D centers…
Good health is vital to all of us, and finding sustainable solutions to the most pressing health care challenges of our world cannot wait. That’s why we at Pfizer are committed to applying science and our global resources to improve health and well-being at every stage of life. We strive to provide access to safe, effective and affordable medicines and related health care services to the people who need them.
To ensure we can continue to deliver on our commitments to the patients, customers and shareholders who rely on us, we are focused on improving the way we do business; on operating with transparency in everything we do; and on listening to the views of all of the people involved in health care decisions. Through working in partnership with everyone from patients to health care providers and managed care organizations to world governments and non-governmental organizations, our goal is to ensure that people everywhere have access to innovative treatments and quality health care.
Good health is vital to all of us, and finding sustainable solutions to the most pressing health care challenges of our world cannot wait. That’s why we at Pfizer are committed to applying science and our global resources to improve health and well-being at every stage of life. We strive to provide access to safe, effective and affordable medicines and related health care services to the people who need them.
To ensure we can continue to deliver on our commitments to the patients, customers and shareholders who rely on us, we are focused on improving the way we do business; on operating with transparency in everything we do; and on listening to the views of all of the people involved in health care decisions. Through working in partnership with everyone from patients to health care providers and managed care organizations to world governments and non-governmental organizations, our goal is to ensure that people everywhere have access to innovative treatments and quality health care.
Contact:
Address: German Center, Tower 1, 5F, 88 Keyuan Rd, Pudong Zhangjiang Hi-Tech Park, Shanghai, P.R.China 201203
Tel: (021) 28935888
It seems like there’s a lot to be happy about here: Pfizer is ranked number 1 multinational R&D-based biopharmaceutical company in China, where you also have two world-class R&D centers…
Pierre Faury, co-President of the French Healthcare Alliance in China as well as vice-President of Sanofi China in charge of Commercial Excellence, shares the mandate of the French Healthcare Alliance…
Tony Au, general manager of AbbVie China, shares the key milestones for the affiliate in the past six years, the strong foundation he has built for AbbVie in China, the…
China is set to become the second largest market for Mundipharma’s OxyContin behind the US. It comes as no surprise that sales of opioids such as OxyContin have plummeted…
Dr Dan Zhang, CEO of Fountain Medical Development (FMD), details the transformation China’s recent membership at the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human…
Dr Wang Yinxiang, chairman; and Dr Hu Shaojing, President (R&D); of Jacobio Pharmaceutical; share the exciting story behind Jacobio’s establishment in 2015, their ambition to become a global biopharma player…
Alan Chen, general manager for Ipsen China, shares the exciting journey of Ipsen in China in the past few years as the third-largest affiliate for the group globally, upcoming innovative…
Dr Michael Yu, founder, Chairman and CEO of Innovent Biologics, one of China’s most successful and innovative biopharma start-up, shares his long-term vision to build a company that can last…
Rogier Janssens, GM of the Biopharma business of Merck KGaA, Darmstadt, Germany in China, shares the highlights of his first 16 months at the affiliate; the impact of the regulatory…
Kang Wei, managing director for the R&D-based Pharmaceutical Association Committee (RDPAC) under the China Association of Enterprises with Foreign Investment, shares her priorities for RDPAC in the next few years,…
Aditya Bhattacharji manages Eurasia Group‘s healthcare analysis and Kevin Allison is the director of geo-technology. Together they look at last week’s shock revelation of two CRISPR* babies who were born in China and…
Steven Lynch, managing director of the British Chamber of Commerce in China, introduces the Chamber’s activities in support of their members, the research they are undertaking to produce a position…
Song Ruilin, executive president of the China Pharmaceutical Innovation and Research Development Association (PhIRDA), discusses his association’s mandate, key achievements and the future of innovative Chinese pharmaceuticals and biotech. …
See our Cookie Privacy Policy Here